These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 34206739)

  • 1. Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders.
    Mor A; Tankiewicz-Kwedlo A; Krupa A; Pawlak D
    Cells; 2021 Jun; 10(7):. PubMed ID: 34206739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K; Robotka H; Toldi J; Vécsei L
    J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kynurenine pathway and neurodegenerative disease.
    Maddison DC; Giorgini F
    Semin Cell Dev Biol; 2015 Apr; 40():134-41. PubMed ID: 25773161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
    Boros FA; Bohár Z; Vécsei L
    Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
    Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.
    Shen H; Xu X; Bai Y; Wang X; Wu Y; Zhong J; Wu Q; Luo Y; Shang T; Shen R; Xi M; Sun H
    Eur J Med Chem; 2023 May; 251():115258. PubMed ID: 36917881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders.
    O'Farrell K; Harkin A
    Neuropharmacology; 2017 Jan; 112(Pt B):307-323. PubMed ID: 26690895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives.
    Ciapała K; Mika J; Rojewska E
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
    Lovelace MD; Varney B; Sundaram G; Lennon MJ; Lim CK; Jacobs K; Guillemin GJ; Brew BJ
    Neuropharmacology; 2017 Jan; 112(Pt B):373-388. PubMed ID: 26995730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phytochemical treatments target kynurenine pathway induced oxidative stress.
    Parasram K
    Redox Rep; 2018 Dec; 23(1):25-28. PubMed ID: 28651456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection.
    Sas K; Szabó E; Vécsei L
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29342113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kynurenine pathway, NAD
    Castro-Portuguez R; Sutphin GL
    Exp Gerontol; 2020 Apr; 132():110841. PubMed ID: 31954874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.
    Amaral M; Outeiro TF; Scrutton NS; Giorgini F
    J Mol Med (Berl); 2013 Jun; 91(6):705-13. PubMed ID: 23636512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
    Fujigaki H; Yamamoto Y; Saito K
    Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.
    Zádori D; Klivényi P; Plangár I; Toldi J; Vécsei L
    J Cell Mol Med; 2011 Apr; 15(4):701-17. PubMed ID: 21155972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system.
    Colín-González AL; Maldonado PD; Santamaría A
    Neurotoxicology; 2013 Jan; 34():189-204. PubMed ID: 23219925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 'Yin' and the 'Yang' of the kynurenine pathway: excitotoxicity and neuroprotection imbalance in stress-induced disorders.
    Barone P
    Behav Pharmacol; 2019 Apr; 30(2 and 3-Spec Issue):163-186. PubMed ID: 30844963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.
    Behl T; Kaur I; Sehgal A; Singh S; Bhatia S; Al-Harrasi A; Zengin G; Bumbu AG; Andronie-Cioara FL; Nechifor AC; Gitea D; Bungau AF; Toma MM; Bungau SG
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.